Most BRCA mutations identified in patients with prostate cancer are somatic, and, compared with low mutation levels in early prostate cancer, ∼15% of patients with metastatic androgen therapy–resistant prostate cancer harbor functionally relevant somatic mutations or deletions in BRCA1 or BRCA2 (Robinson et al. 2015). This evidence concerns the gene BRCA2 and Familial prostate cancer.